QTTB Stock — Q32 Bio Inc.

Q32 Bio Inc. (QTTB)

Updated October 16, 2026.

QTTB is a Stock. Total return is -97.8% over the past 8.6 years, 331.9 points behind SPY at 234.1%.

Q32 Bio Inc. is a clinical-stage biotechnology company developing novel monoclonal antibodies and fusion proteins to treat autoimmune and inflammatory diseases, including alopecia areata and atopic dermatitis. The company's lead candidate, bempikibart, is an anti-interleukin-7 receptor antagonist that has completed Phase 2a trials; it also has pipeline programs targeting ophthalmologic conditions through complement inhibition. Q32 Bio does not currently distribute to shareholders.

QTTB performance versus SPY

Price and return data through 2026-10-16.

Total return is -97.8% over the past 8.6 years, 331.9 points behind SPY at 234.1%. Over the past year its total return — price change plus distributions reinvested — is 108.9%. Its deepest 1-year drawdown was 64.8%.

QTTB key facts

Asset type

Stock

Asset class

Equity

Inception date

03/28/2018

Distribution frequency

None

Last close

$7.52 (as of 2026-10-16)

Market cap

$223,866,384

Average volume

677992.0

Beta

-0.109

Payout ratio

0.0%

P/E ratio

2.39

EPS

$3.15

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

QTTB risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 64.8%.

Who may consider QTTB — and who may not

It is a weaker fit for investors who need monthly cash flow (QTTB does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on QTTB

• All tickers starting with Q

Tagged: Healthcare.

Frequently asked questions